Pharmacotherapy and Intensive Treatment of Drug Abuse - 1

The purpose of this study is to evaluate desipramine and carbamazepine in reducing cocaine craving; increase outpatient treatment capacity and evaluate their incidence of psychiatric disorders...

Date First Received: September 20, 1999

Last Updated: June 23, 2005

Verified by: National Institute on Drug Abuse (NIDA), December 2002

Clinical Trial Phase: Phase 2 | Start Date: 

Overall Status: Completed

Estimated Enrollment: 0

Brief Summary

Official Title: “Pharmacotherapy and Intensive Treatment of Drug Abuse”

Intervention(s):

The purpose of this study is to evaluate desipramine and carbamazepine in reducing cocaine craving; increase outpatient treatment capacity and evaluate their incidence of psychiatric disorders.

Study Type: Interventional

Study Design: Treatment

Intervention(s) in this Clinical Trial

  • Drug: Carbamazepine

Outcome Measures for this Clinical Trial

Primary Measures

  • Drug use
  • Effectiveness of medication
  • Level of pharm
  • Retention
  • Depression, anxiety

Criteria for Participation in this Clinical Trial

  • Please contact site for information.

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: 60 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Clinical Trial Sponsor Information

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Overall Clinical Trial Officials and Contacts

William Haning, M.D. Principal Investigator University of Kansas  

Additional Information

Information obtained from ClinicalTrials.gov on August 29, 2008

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00000217

Study ID Number: NIDA-06954-1

ClinicalTrials.gov Identifier: NCT00000217

Health Authority: United States: Federal Government

Clinical Trials Authorship and Review

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.